Advancing Drug Discovery & Development Through Science & Services
Axela Biosciences Inc. was established in 2024 through the merger of PicoImmune (also known as NanoBiotec) and EmerTher USA—two organizations with over a decade of proven expertise in biopharmaceutical contract research and life science innovation. Headquartered in Whippany, New Jersey, Axela combines deep scientific acumen with operational agility to deliver high-performance bioassays, biomarker discovery platforms, and bioanalytical services that support every stage of drug discovery and translational development.
Our integrated infrastructure leverages advanced instrumentation, automation, and regulatory-compliant workflows to provide robust, data-driven solutions tailored to the evolving needs of our partners. In addition to our core discovery and translational capabilities, we offer a curated portfolio of research products, including immune cell reagents and assay kits, to enable faster and more reliable results.
Our multidisciplinary team—spanning immunology, molecular and cell biology, and bioengineering—collaborates closely with emerging biotech companies, global pharmaceutical firms, and academic institutions. Together, we accelerate the development of precision therapeutics and diagnostics in high-impact areas, particularly in oncology, immunology, inflammatory diseases, and other disease areas with unmet medical need.
Oncology, Hematology, Immuno-Oncology
Comprehensive cancer biology support with flow cytometry, immune profiling, and functional monitoring.
Immunology & Inflammation
Expertise in allergy, autoimmunity, rheumatology, and dermatology using robust inflammatory assay platforms.
Biomarker Discovery & Validation
End-to-end biomarker solutions from discovery to CLIA-certified assay development and validation.
Spatial Genomics, Transcriptomics & Proteomics
Advanced spatial biology with NanoString GeoMx® and nCounter® for multi-omics analysis.
Small Molecule Discovery
Expertise in kinase inhibitors, degraders, and molecular glues to drive drug development.
Large Molecule Therapeutics
Expertise in antibodies, bispecifics, and ADCs from target validation to functional testing.
Novel Therapeutic Modalities
Advancing siRNA, peptides, CAR-T, iPSCs, and other emerging therapies.
High-Throughput Screening & Automation
Scalable platforms for rapid screening of compounds and immune modulators.
Target Identification & Mechanism of Action (MOA)
Integrated strategies to identify targets and define drug mechanisms in disease models.
Patient Stratification & Companion Diagnostics
Translational insights for personalized medicine through biomarker-guided patient selection and diagnostic co-development.